A 66-year-old patient, undergoing heart surgery, developed an anaphylactic reaction following the first administration of a test-dose of aprotinin. Skin tests were performed six months later. Prick-tests with 10(-2) and 10(-1) aprotinin dilutions were negative but intradermal reaction with a 10(-3) dilution was clearly positive. The level of aprotinin specific IgE was high, both in the serum obtained before surgery and in the one sampled on the day of the testing. As no reaction was observed during the tests, skin-testing and specific IgE appear to be an interesting alternative to a potentially dangerous test-dose, but they both need further evaluation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0750-7658(00)00318-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
InterDIA: Interpretable Prediction of Drug-induced Autoimmunity through Ensemble Machine Learning Approaches.
Toxicology
January 2025
Deparment of clinical pharmacy, Jieyang People's Hospital, 522000, China. Electronic address:
Drug-induced autoimmunity (DIA) is a non-IgE immune-related adverse drug reaction that poses substantial challenges in predictive toxicology due to its idiosyncratic nature, complex pathogenesis, and diverse clinical manifestations. To address these challenges, we developed InterDIA, an interpretable machine learning framework for predicting DIA toxicity based on molecular physicochemical properties. Multi-strategy feature selection and advanced ensemble resampling approaches were integrated to enhance prediction accuracy and overcome data imbalance.
View Article and Find Full Text PDFMHC Class II-Expressing Mucosal Mast Cells Promote Intestinal Mast Cell Hyperplasia in a Mouse Model of Food Allergy.
Allergy
January 2025
Department of Pediatrics and Adolescent Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Background: IgE-mediated food allergy is accompanied by mucosal mast cell (MMC) hyperplasia in the intestinal mucosa. Intestinal MMC numbers correlate with the severity of food allergy symptoms. However, the mechanisms by which MMCs proliferate excessively are poorly understood.
View Article and Find Full Text PDFComparison of the new RIDA qLine Allergy multiparameter immunoblot and the ImmunoCAP Specific IgE test for the identification of clinically relevant food and aeroallergen allergies.
Front Allergy
January 2025
Department of Dermatology, Venereology and Allergology, University Medical Centre Goettingen, Goettingen, Germany.
Background: Multiparameter immunoblot testing is increasingly used as an alternative to multiple individual IgE analyses for type 1 allergies. This study investigated the performance of an inexpensive immunoblot method, the RIDA qLine allergy test system (R-Biopharm AG), vs. the current gold standard.
View Article and Find Full Text PDFA nomogram for predicting bladder dysfunction in patients with type 2 diabetes mellitus: a retrospective study.
PeerJ
January 2025
Department of Nursing, Shenzhen Hospital, Southern Medical University, Shenzhen, Guangdong, China.
Background: Diabetic bladder dysfunction (DBD) is a common urinary complication in diabetic patients, significantly affecting their overall well-being and quality of life, and placing a considerable burden on healthcare resources. Early prevention is crucial; however, the absence of a simple and effective tool to predict DBD onset remains a significant challenge. This study aims to identify risk factors for DBD in patients with type 2 diabetes mellitus (T2DM) and to develop a predictive nomogram for clinical application.
View Article and Find Full Text PDFTheoretical and practical considerations for validating antigen-specific B cell ImmunoSpot assays.
J Immunol Methods
January 2025
Research & Development Department, Cellular Technology Limited, Shaker Heights, OH 44122, USA. Electronic address:
Owing to their ability to reliably detect even very rare antigen-specific B cells in cellular isolates such as peripheral blood mononuclear cells (PBMC), and doing so robustly in a high throughput-compatible manner, B cell ELISPOT/FluoroSpot (collectively "B cell ImmunoSpot") tests have become increasingly attractive for immune monitoring in regulated settings. Presently, there are no guidelines for the qualification and validation of B cell ImmunoSpot assay results. Here, we propose such guidelines, building on the experience acquired from T cell ImmunoSpot testing in an environment adhering to the requirements of regulatory bodies yet taking the unique features of B cell assays into account.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!